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Objectives: To determine if, in the short term, acetic acid and dexamethasone iontophoresis combined
with LowDye (low-Dye) taping are effective in treating the symptoms of plantar fasciitis.
Methods: A double blinded, randomised, placebo controlled trial of 31 patients with medial calcaneal
origin plantar fasciitis recruited from three sports medicine clinics. All subjects received six treatments of
iontophoresis to the site of maximum tenderness on the plantar aspect of the foot over a period of two
weeks, continuous LowDye taping during this time, and instructions on stretching exercises for the
gastrocnemius/soleus. They received 0.4% dexamethasone, placebo (0.9% NaCl), or 5% acetic acid.
Stiffness and pain were recorded at the initial session, the end of six treatments, and the follow up at four
weeks.
Results: Data for 42 feet from 31 subjects were used in the study. After the treatment phase, all groups
showed significant improvements in morning pain, average pain, and morning stiffness. However for
morning pain, the acetic acid/taping group showed a significantly greater improvement than the
dexamethasone/taping intervention. At the follow up, the treatment effect of acetic acid/taping and
dexamethasone/taping remained significant for symptoms of pain. In contrast, only acetic acid
maintained treatment effect for stiffness symptoms compared with placebo (p = 0.031) and
dexamethasone.
Conclusions: Six treatments of acetic acid iontophoresis combined with taping gave greater relief from
stiffness symptoms than, and equivalent relief from pain symptoms to, treatment with dexamethasone/
taping. For the best clinical results at four weeks, taping combined with acetic acid is the preferred
treatment option compared with taping combined with dexamethasone or saline iontophoresis.
P
lantar fasciitis (PF) causes pain and stiffness in the heel
and medial arch of the plantar surface of the foot and
can interfere considerably with activities of daily
living.1 2 It is common in the community and prevalent
among those participating in running sports.3
Patients with PF report pain and/or stiffness localised to
their heel which may extend distally to the arch of the foot.4
The typical patient describes symptoms during the first steps
after rising in the morning.5 In most patients these symptoms
vary in intensity and may settle or resolve after a variable
period from a few steps to a few hours. In most cases,
symptoms then increase as the day progresses.3 6 7 On
palpation of the heel, tenderness is focal and localised to
the medial calcaneal origin of the plantar fascia.3
Various treatment strategies, including orthoses,7–10
stretching,11–15 taping,10 16 extracorporeal shock wave ther-
apy,17 18 laser therapy,19 and drug therapy in the form of
systemic medication,11 percutaneous injection20–22, and topical
application,23 24 have been investigated and have shown
variable clinical benefit.
Two studies have shown clinically relevant improvements
in PF symptoms using iontophoresis of dexamethasone23 and
acetic acid.24 Non-steroidal anti-inflammatory drugs have
been trialled,25 but did not show clinically significant effects.
LowDye (low-Dye) taping26 supports the longitudinal arch
of the foot. It has been shown to significantly reduce peak
plantar pressures of normal feet during gait, especially the
peak plantar pressure in the medial midfoot,16 27 so it might
be expected to play a role in the management of PF. There are
no reports in the literature of the use or efficacy of LowDye
taping in the treatment of PF symptoms. HighDye taping has
been shown to reduce rear foot eversion when walking but
not LowDye taping.28 One limitation of long term taping is
that there is potential for skin breakdown, and therefore it
may be considered only as a short term management option
usually combined with adjunct therapies.
No studies have examined how taping interacts with drug
therapy during short term treatment of PF. The purpose of
this study was to determine the short term efficacy of
iontophoresis of acetic acid and dexamethasone combined
with LowDye taping support.
METHODS
Subjects
Subjects were recruited from three sports medicine clinics
over one year. They provided informed consent as approved
by the institutional human research ethics committee.
Patients who met the diagnostic criteria were referred for
plain non-weight bearing radiographs of the foot and
diagnostic ultrasound.
Subjects were included in the study if they fulfilled the
following criteria:
(a) aged 18–75 years, with heel pain for more than one
month consistent with a history of PF
(b) clinical diagnosis of PF of medial calcaneal origin based
on patient history and physical examination
545
www.bjsportmed.com
Subjects were excluded from the study if they had:
(a) contraindications to dexamethasone, acetic acid, taping,
or iontophoresis
(b) specific pathology from trauma or other coexisting
symptomatic foot pathology requiring treatment
(c) calcaneal stress fracture, gout, bone tumour, osteomye-
litis, diabetes
(d) surgery for PF within the previous six months
(e) new orthotics or corticosteroid treatment in the
previous month
(f) abnormal erythrocyte sedimentation rate or C reactive
protein or HLA-B27 positive
Interventions
Patients with PF were randomly assigned to one of three
groups using computer generated block randomisation.
During the treatment phase, patients received six treat-
ments of iontophoresis to the site of maximum tenderness on
the plantar aspect of the foot. They received 0.4% dexa-
methasone, placebo (0.9% NaCl), or 5% acetic acid, delivered
using the Phoresor II Iontophoresis Drug Delivery System
(IOMED, Inc, Salt Lake City, Utah, USA). Current was
applied up to 4 mA, and a total dose of 40 mA.min was
delivered over a period of time determined by the patient’s
sensitivity. The six treatments were delivered on alternating
days over a period of two weeks. At each treatment session,
the LowDye taping was renewed, so that all subjects were
continuously taped for two weeks. The subjects were
reminded to perform two stretching exercises for the
gastrocnemius/soleus muscle group for one minute twice
daily.
The three drugs were dispensed into three identical colour
coded bottles, and all randomisations were performed
independently and concealed from the treating researcher
and patient.
Before all iontophoretic treatments, the dorsum of the
target foot was wiped with acetic acid (household vinegar) to
mask the smell of the different solutions and minimise the
chance of the patient and treating doctor being unblinded to
the group allocation.
Measurements of primary outcomes were repeated at two
week intervals (baseline, after treatment, and at follow up).
At the completion of the treatment, the patient recorded
which drug they thought had been used to determine if
masking had been successful.
Outcome measures
Pain and stiffness were the two primary symptoms exam-
ined. These were assessed using a series of horizontal visual
analogue scales where zero reflected the total absence of
symptoms and 10 the worst imaginable pain or stiffness.
Pain visual analogue scale assessments included:
N worst pain in the last two days
N average pain in the last two days
N pain on first rising on the morning of the assessment
N residual pain (the pain remaining after the morning pain
settles down with activity)
Stiffness visual analogue scale assessments were:
N stiffness on first rising on the morning of the assessment
N residual stiffness (the stiffness remaining after the
morning stiffness settles down with activity)
We also recorded duration of morning stiffness (how long
it took for the morning stiffness to settle down with activity).
Statistical analysis
Basic data were expressed as mean (SD). The raw data of the
three repeated measures of the primary outcomes were
converted into absolute change scores compared with the
baseline score. Positive values reflected positive clinical effect,
with the mean and 95% confidence interval (CI) shown in
figures. Statistically significant changes were identified when
the 95% CI did not include zero change.
Statistically significant differences between groups were
determined using analysis of covariance with the initial
baseline score as the covariant, and treatment groups as the
between factor.29 Post hoc differences were determined using
a Fisher’s PLSD post hoc comparison. Processing was
performed using StatView (SAS Institute Inc) and Excel
(Microsoft Office). Statistical significance was set at p,0.05.
A x2 contingency table was used to determine if subjects
were able correctly determine better than chance their group
allocation.
RESULTS
Tables 1 and 2 show the basic characteristics of the subjects
and the baseline scores for the primary symptoms respec-
tively. There were no group differences at baseline across all
variables (all values p.0.249).
There were no withdrawals, and all subjects returned for
the follow up two weeks after the sixth treatment. One cell of
follow up data was lost, and the end treatment value was
used in subsequent analyses.
Figure 1 shows the treatment effect for the pain symptoms.
All groups showed a significant improvement in morning
pain and average pain in the past week. However, for
morning pain, the acetic acid/taping showed significantly
greater improvement than the dexamethasone/taping inter-
vention. This trend was apparent for residual pain and worst
pain in past two days where the dexamethasone/taping
intervention was the only group not to reach statistical
significance.
Figure 2 shows the stiffness change scores for the two
week interventions. All interventions produced significant
improvements in morning stiffness. The placebo/taping and
Table 1 Basic characteristics of the three treatment groups
Placebo Dexamethasone Acetic acid Total
No of patients 10 11 10 31
Bilateral 2 4 5 11
Age (years) 52.2 (10.7) 49.3 (13.3) 52.0 (7.7) 51.1 (10.6)
Duration of symptoms (months) 7.5 (5.0) 8.1 (7.5) 18.6 (19.2) 11.8 (13.5)
Sex (M:F) 4:6 3:8 7:3 14:17
Weight (kg) 80.4 (18.0) 79.2 (11.0) 89.1 (17.4) 83.4 (16.2)
Height (cm) 167.3 (11.4) 170.1 (8.5) 169.9 (8.6) 169.2 (9.3)
Body mass index 28.6 (7.7) 28.1 (4.0) 31.2 (7.3) 29.4 (6.6)
Where applicable, values are mean (SD).
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acetic acid/taping groups showed significantly less residual
stiffness, whereas this did not reach significance in the
dexamethasone/taping group. The placebo/taping group
showed significant reduction in the duration of morning
stiffness.
Figures 3 and 4 show the change scores from the baseline
to the four week follow up. The additional grey markers show
the mean change score at the end of the treatment phase.
Note that, for the pain symptoms, acetic acid/taping and
placebo/taping showed a loss of treatment effect. This is
particularly clear for placebo/taping, where the gains during
taping are lost and none of the change scores are significant
at the 95% confidence level. In comparison, the decline in
pain symptoms response is small for acetic acid/taping and
the gains remain significant. The dexamethasone/taping
group showed a continued improvement from the initial
two weeks of treatment. This may be because this interven-
tion was not very effective in the initial two weeks.
The stiffness follow up data show a different pattern.
Relatively large losses of treatment effect in the placebo/
taping and dexamethasone/taping treatments are seen
compared with the maintained treatment response of the
acetic acid/taping group. In the acetic acid/taping group,
significance for morning stiffness and residual stiffness was
maintained, and this reflected a significant difference
between this group and the placebo/taping group (p =
0.031).
Several patients reported pain that did not ease off in the
morning and lasted all day. There were no patients who
reported stiffness that did not resolve after a period of time.
Five patients developed skin irritation from taping; one
patient found the tape very uncomfortable and in two
patients the skin did not tolerate the mechanical loading
and peeled. Four of these patients did not complete the full
course of taping but all completed the course of iontophor-
esis. Of these four patients, two were in the placebo group
and one in each of the active drug treatment groups. No
patients needed treatment for these skin problems other than
cessation of taping.
Patients did not guess the group to which they were
allocated with more accuracy than chance (x2 = 0.150, p =
0.699).
DISCUSSION
The results of the study suggest that taping (combined with
limited stretching) provides initial short term reduction of
both pain and stiffness symptoms in people with PF when
Table 2 Main outcome variables at baseline for the three treatment groups
Outcome variable Placebo Dexamethasone Acetic acid Total
Number of feet 12 15 15 42
Worst pain last 2 days 60.7 (14.9) 64.5 (23.4) 54.5 (23.6) 59.8 (21.3)
Average pain last 2 days 46.3 (16.2) 52.5 (24.3) 36.3 (24.0) 45.0 (22.7)
Morning stiffness 44.3 (31.7) 43.9 (35.7) 51.5 (28.4) 46.7 (31.5)
Residual stiffness 25.9 (19.7) 15.9 (19.8) 27.8 (17.0) 23.0 (19.2)
Minutes stiffness 9.4 (11.0) 8.0 (10.4) 10.6 (8.1) 9.3 (9.7)
Morning pain 50.1 (32.0) 55.9 (27.1) 49.5 (30.4) 52.0 (29.1)
Residual pain 38.7 (27.8) 33.3 (24.0) 33.0 (26.5) 34.7 (25.5)




















Figure 1 Pain change score responses (mean and 95% confidence
interval) for the three treatment groups after two weeks of intervention.
All scores are related to a 10 cm visual analogue scale, and positive












Figure 2 Stiffness change score responses (mean and 95% confidence
interval) for the three treatment groups after two weeks of intervention.
Duration of morning stiffness in minutes and other stiffness scores are
related to a 10 cm visual analogue scale, and positive changes reflect
clinical benefit.
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used with placebo or acetic acid iontophoresis. In terms of the
ability to maintain these changes after an additional two
weeks of no intervention, it is clear that this effect was
maintained in the acetic acid group, whereas the greatest
attenuation of relief—that is, return—of both pain and
stiffness symptoms occurred in the placebo group.
The benefits of taping found in this study are consistent
with research in which mechanical adaptations—that is,
taping, orthoses—are prescribed.8 9 In the clinical setting,
LowDye taping results in almost immediate changes in
symptoms. It is proposed that, during this short term
alleviation of symptoms, the adjunct management options
have time to reach therapeutic thresholds.
Continuous taping, however, is difficult as patients become
sensitive to the tape. This may lead to skin breakdown. In this
study, the two weeks of taping resulted in about 23% of cases
in which there were clinically noticeable changes to the skin
by the end of the two weeks. This suggests that longer term
use of taping may be problematic and any adjunct interven-
tion that prolongs the treatment effect would be of great
benefit.
The results for the dexamethasone/taping group showed a
different pattern of response. Firstly, this group tended not to
show the magnitude of improvement of the other two groups
at the end of the initial treatment. Acetic acid produced
significantly greater improvements in morning pain than
dexamethasone. The change scores of the dexamethasone
group failed to reach significance for the worst pain and
residual stiffness scores unlike the other two groups.
Secondly, continued resolution of the pain during the no
treatment period was only observed in the dexamethasone
group. This was observed for all the assessments of pain.
It is unclear why, or if, the LowDye taping affected the
effectiveness of the dexamethasone, as it would seem that
this combination did not achieve the same early responses as
the acetic acid/taping and placebo/taping alone.
Importantly, although the continued improvement in pain
symptoms of the dexamethasone group during the no
treatment period is clear, the group change scores provide
no evidence that it outperformed acetic acid across either
domain of pain or stiffness at any assessment point.
One aspect of interest was the different responses to pain


















Figure 3 Pain change score responses (mean and 95% confidence
interval) from initial assessment to four week follow up for the three
treatment groups. All scores are related to a 10 cm visual analogue
scale, and positive changes reflect clinical benefit. Grey markers show
status at the end of the two week intervention showing level of
maintenance/loss of clinical effect. Note that placebo/taping tended to















stiffness p = 0.031
Figure 4 Stiffness change score responses (mean and 95% confidence
interval) from initial assessment to four week follow up for the three
treatment groups. Grey markers show status at the end of the two week
intervention showing level of maintenance/loss of clinical effect. Note
that maintenance of clinical benefit is most obvious in acetic acid/taping
group.
What is already known on this topic
N Two studies have looked at iontophoresis of drugs for
the treatment of plantar fasciitis; one is a randomised,
placebo controlled trial using dexamethasone that
shows good outcomes from this treatment
N The other is an uncontrolled clinical trial of acetic acid
with outcomes that are perhaps better than that of
dexamethasone
What this study adds
N This study shows that both drugs, when delivered via
iontophoresis in combination with LowDye taping, give
good short term relief, with acetic acid being at least as
good as, if not better than, dexamethasone
N The benefits of taping are reduced when it is stopped;
however, when it is combined with iontophoresis,
treatment effects are maintained
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greatest clinical response of acetic acid/taping was the
alleviation of morning stiffness where the sustained improve-
ments in the dexamethasone group were noted only for pain.
These findings may suggest that the symptoms of PF that
reduce function are pain and stiffness, and there may be
slight differences in the type of symptoms people experience.
This may reflect subgroups within the PF population and
therefore may have a prognostic value in the choice of
intervention. Further research may suggest different combi-
nations of interventions to target the primary symptomatic
complaint.
The timeline of the intervention was relatively short and of
a mixed (intervention) mode. Rapid change in the primary
symptoms that restrict the activities of daily living was the
basis for the research design. This reflects the current clinical
practice of many treating physicians.
CONCLUSION
This study found that a protocol of six treatments of acetic
acid iontophoresis combined with taping provides greatest
relief of the stiffness symptoms of PF. LowDye taping
provides a short term window of opportunity in the
management of symptoms of PF. Once taping is stopped,
this effect wears off, but, if iontophoresis of acetic acid or
dexamethasone is used in combination with taping, sig-
nificant treatment effects persist at four weeks. For the best
clinical results at four weeks, acetic acid iontophoresis/
LowDye taping is the preferred treatment option over
dexamethasone iontophoresis/LowDye taping or taping
alone.
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. . . . . . . . . . . . . . COMMENTARY . . . . . . . . . . . . . .
This paper adds scientifically sound information to a number
of treatments that have been relatively little researched.
Clinical relevance is limited by the short period of follow up
and the fact that at present there are few other studies with
which to compare.
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